Inosine

General characteristics. Structure:

Active agent: inosine — 200 mg
 
 Excipients: (kernel): cellulose microcrystallic — 40,0 mg, sucrose — 40,0 mg, potato starch — 17,0 mg, povidone (polyvinylpirrolidone) — 10,0 mg, croscarmellose sodium — 6,0 mg, magnesium stearate — 3,0 mg, the water purified — 4,0 mg.

Excipients (cover): a gipromelloza — 5,5 mg, polysorbate-80 — 1,5 mg, titanium dioxide — 3,0 mg.

Pharmacological properties:

Pharmacodynamics. Metabolic means, predecessor of ATP; has antigipok-sichesky, metabolic and antiarrhytmic effect. Increases power balance of a myocardium, improves coronary circulation, prevents effects of intraoperative ischemia of kidneys. Is directly involved in exchange of glucose and promotes activation of exchange in the conditions of a hypoxia and in the absence of ATP. Activates metabolism of pyruvic acid for ensuring normal process of tissue respiration, and also promotes activation of a xanthinedehydrogenase. Stimulates synthesis of nucleotides, increases activity of some enzymes of a tricarbonic acid cycle. Getting into cells, raises energy level, has positive effect on processes of exchange in a myocardium — increases force of reductions of heart and promotes fuller relaxation of a myocardium in a diastole therefore the stroke output increases. Reduces aggregation of thrombocytes, activates an angenesis (especially a myocardium and a mucous membrane of the digestive tract (DT)).

Pharmacokinetics. It is well absorbed in a GIT. It is metabolized in a liver with formation of glucuronic acid and the subsequent its oxidation. In insignificant quantity it is allocated with kidneys.

Indications to use:

Appoint the adult in complex therapy of coronary heart disease, a myocardial dystrophy, after a myocardial infarction, the disturbances of a heart rhythm caused by use of cardiac glycosides. Appoint at hepatitises, cirrhosis, fatty dystrophy of the liver caused by alcohol or medicines and urokoproporfiriya.

Route of administration and doses:

Appoint inside to food. The daily dose at intake makes 0,6-2,4 g. In the first days of treatment the daily dose is equal to 0,6-0,8 g (on 0,2 g 3-4 times a day). In case of good tolerance the dose is raised (for 2-3 day) on 1,2 g (0,4 g 3 times a day), if necessary — to 2,4 g a day. Course duration — from 4 weeks to 1,5-3 months.
At  an urokoproporfiriya  the daily dose makes 0,8 g (on 0,2 g 4 times a day). Drug is accepted daily within 1-3 months.

Features of use:

There are no data.

Side effects:

Allergic reactions in the form of a small tortoiseshell, a skin itch, a dermahemia are possible (drug withdrawal is required). Seldom at treatment by drug concentration of uric acid in blood and an exacerbation of gout (increases at prolonged use).

Interaction with other medicines:

There are no data.

Contraindications:

Hypersensitivity to drug, gout, a hyperuricemia. Pregnancy, lactation period. Age up to 18 years.

With CARE - a renal failure.

Overdose:

There are no data.

Storage conditions:

List B. To store in the dry, protected from light place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets, film coated, on 200 mg.
On 10, 25 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 10, 20, 30, 40, 50 or 100 tablets in a container polymeric for medicines.
One container or 1, 2, 3, 4, 5 or 10 blister strip packagings together with the application instruction place in a pack from a cardboard.